These Juno investors will cash out big in Celgene's $9 billion takeover

Juno Therapeutics  Inc.'s top investors will cash out stock worth hundreds of millions of dollars in the biotech company’s pending acquisition by Celgene Corp. Celgene's $9 billion takeover of Seattle-based Juno is priced at $87 per share. Summit, New Jersey-based Celgene already owns $900.5 million worth of Ju no stock. Celgene bought about $850 million worth of Juno stock (at $93 per share) in 2015 and paid Juno $150 million in cash for options to develop and commercialize Juno’s immunotherapy…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news